Mary Jo Lamberti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary Jo Lamberti has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Ken Getz
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA
5 shared publications- Kenneth Getz
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, USA
3 shared publications Deborah Howe
Global Recruitment and Analytics, Bristol-Myers Squibb, Wallingford, CT, USA
2 shared publicationsJosephine Awatin
Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA
2 shared publicationsMichael Wilkinson
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA
2 shared publications- Abigail Dirks
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, USA
1 shared publication
Latest Publications
- 29 May 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1-13
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical Development
Background The use of artificial intelligence (AI) and machine learning (ML) in drug discovery has been well documented, but measures of levels of adoption, investments, and efficiencies gained from its use in clinical development have not yet been developed, captured or published. AI/ML use in clinical development is expected to increase, but its impact has not yet been systematically measured until now. Methods The Tufts Center for the Study of Drug Development conducted a global online survey among pharmaceutical and biotechnology companies, contract research organizations (CROs), and data and technology vendors servicing drug developers. The survey gathered 302 responses assessing levels of AI/ML implementation across 36 distinct clinical trial planning and design, trial execution, and regulatory submission activities. The survey collected data on US dollar investment, time savings, and challenges and opportunities of AI/ML use in clinical development. Results Approximately one-third of the sample (36.9%) was not yet using or implementing AI/ML across 36 design and planning, execution, and regulatory submission activities; another 30.3% was beginning their AI/ML implementation (or piloting), 22.1% was partially implementing (or moving beyond pilots), and on average only 10.7% had fully implemented AI/ML (i.e., uses AI in most trials employing a repeatable process).
- 29 May 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1-13
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical Development
Background The use of artificial intelligence (AI) and machine learning (ML) in drug discovery has been well documented, but measures of levels of adoption, investments, and efficiencies gained from its use in clinical development have not yet been developed, captured or published. AI/ML use in clinical development is expected to increase, but its impact has not yet been systematically measured until now. Methods The Tufts Center for the Study of Drug Development conducted a global online survey among pharmaceutical and biotechnology companies, contract research organizations (CROs), and data and technology vendors servicing drug developers. The survey gathered 302 responses assessing levels of AI/ML implementation across 36 distinct clinical trial planning and design, trial execution, and regulatory submission activities. The survey collected data on US dollar investment, time savings, and challenges and opportunities of AI/ML use in clinical development. Results Approximately one-third of the sample (36.9%) was not yet using or implementing AI/ML across 36 design and planning, execution, and regulatory submission activities; another 30.3% was beginning their AI/ML implementation (or piloting), 22.1% was partially implementing (or moving beyond pilots), and on average only 10.7% had fully implemented AI/ML (i.e., uses AI in most trials employing a repeatable process).
- 3 April 2024
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 58 (4) , 696-703
Benchmarking Site Activation and Patient Enrollment
Clinical trial conduct poses numerous challenges, many pertaining to patient recruitment. The primary objectives of this study were to update benchmarks on site activation and patient enrollment gathered in previous Tufts CSDD studies and examine current usage of recruitment and retention tactics. The data collection focused on site activation and patient enrollment metrics used for studies. Analyses were conducted comparing results from 2012, 2019 and 2023. The results indicate that actual enrollments exceeded planned enrollments for a majority of studies and timelines were shorter than expected. In addition, differences were found for enrollment achievement by global region and site type. Further investigation into studies conducted during a later time frame and post-pandemic could be compared with current benchmarks to examine differences.
- 3 April 2024
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 58 (4) , 696-703
Benchmarking Site Activation and Patient Enrollment
Clinical trial conduct poses numerous challenges, many pertaining to patient recruitment. The primary objectives of this study were to update benchmarks on site activation and patient enrollment gathered in previous Tufts CSDD studies and examine current usage of recruitment and retention tactics. The data collection focused on site activation and patient enrollment metrics used for studies. Analyses were conducted comparing results from 2012, 2019 and 2023. The results indicate that actual enrollments exceeded planned enrollments for a majority of studies and timelines were shorter than expected. In addition, differences were found for enrollment achievement by global region and site type. Further investigation into studies conducted during a later time frame and post-pandemic could be compared with current benchmarks to examine differences.
- 16 June 2020
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 55 (1) , 19-32
Benchmarking Patient Recruitment and Retention Practices
Patient recruitment and retention continue to present challenges in conducting clinical trials. The objectives of the study were to benchmark patient recruitment and retention practices across recent global clinical trials from a working group of biopharmaceutical companies and to re-visit the results from an earlier study published 7 years ago. The data collection focused on patient and site enrollment metrics and recruitment and retention tactics used for studies. Analyses were conducted comparing the results from 2012 and 2019. The results indicated that more studies met or exceeded planned enrollment than the previous research and global differences were observed in the present study for site activation rates and target to actual enrollment rates. Since an updated set of recruitment and retention tactics were evaluated in the present study, no comparisons were made to previous data. Researchers suggest further study that would examine usage and effectiveness of specific recruitment and retention tactics across global studies.
- 16 June 2020
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 55 (1) , 19-32
Benchmarking Patient Recruitment and Retention Practices
Patient recruitment and retention continue to present challenges in conducting clinical trials. The objectives of the study were to benchmark patient recruitment and retention practices across recent global clinical trials from a working group of biopharmaceutical companies and to re-visit the results from an earlier study published 7 years ago. The data collection focused on patient and site enrollment metrics and recruitment and retention tactics used for studies. Analyses were conducted comparing the results from 2012 and 2019. The results indicated that more studies met or exceeded planned enrollment than the previous research and global differences were observed in the present study for site activation rates and target to actual enrollment rates. Since an updated set of recruitment and retention tactics were evaluated in the present study, no comparisons were made to previous data. Researchers suggest further study that would examine usage and effectiveness of specific recruitment and retention tactics across global studies.
- 1 August 2019
- Published by Elsevier in Clinical Therapeutics
- Vol. 41 (8) , 1414-1426
A Study on the Application and Use of Artificial Intelligence to Support Drug Development
- 1 August 2019
- Published by Elsevier in Clinical Therapeutics
- Vol. 41 (8) , 1414-1426
A Study on the Application and Use of Artificial Intelligence to Support Drug Development
- 1 November 2018
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 52 (6) , 778-783
The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies
The adoption and use of real-world evidence (RWE) is becoming increasingly important to drug development and patient safety. The Tufts Center for the Study
- 1 November 2018
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 52 (6) , 778-783
The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies
The adoption and use of real-world evidence (RWE) is becoming increasingly important to drug development and patient safety. The Tufts Center for the Study
- 1 September 2018
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 52 (5) , 572-578
Assessing Study Start-up Practices, Performance, and Perceptions Among Sponsors and Contract Research Organizations
Site identification, site selection, and study start-up have become the focus of improvement by organizations conducting clinical trials. To examine and measure the process from site identification through site activation, Tufts Center for the Study of Drug Development (CSDD) conducted a comprehensive survey among pharmaceutical organizations, biotech companies, and contract research organizations (CROs). Responses from over 400 unique companies were gathered and analyzed. The results indicate that the start-up process is on average 5 to 6 months in total duration, and cycle times across all activities, including site identification, site selection, and study start-up, are faster for repeat sites than for new sites. Comparisons between sponsor and CROs indicate that CROs completed all site-related activities 6 to 11 weeks faster than sponsors. Other areas impacting cycle times were examined, including centralized versus decentralized functions, investment in technology, and organizational strategies that improve cycle time efficiency and performance. Tufts CSDD will explore this area in future research to gather additional insights into other factors that may be associated with speed and efficiency.
- 1 September 2018
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 52 (5) , 572-578
Assessing Study Start-up Practices, Performance, and Perceptions Among Sponsors and Contract Research Organizations
Site identification, site selection, and study start-up have become the focus of improvement by organizations conducting clinical trials. To examine and measure the process from site identification through site activation, Tufts Center for the Study of Drug Development (CSDD) conducted a comprehensive survey among pharmaceutical organizations, biotech companies, and contract research organizations (CROs). Responses from over 400 unique companies were gathered and analyzed. The results indicate that the start-up process is on average 5 to 6 months in total duration, and cycle times across all activities, including site identification, site selection, and study start-up, are faster for repeat sites than for new sites. Comparisons between sponsor and CROs indicate that CROs completed all site-related activities 6 to 11 weeks faster than sponsors. Other areas impacting cycle times were examined, including centralized versus decentralized functions, investment in technology, and organizational strategies that improve cycle time efficiency and performance. Tufts CSDD will explore this area in future research to gather additional insights into other factors that may be associated with speed and efficiency.
- 1 November 2017
- Published by Elsevier in Clinical Therapeutics
- Vol. 39 (11) , 2196-2202
Mapping the Landscape of Patient-centric Activities Within Clinical Research
- 1 November 2017
- Published by Elsevier in Clinical Therapeutics
- Vol. 39 (11) , 2196-2202
Mapping the Landscape of Patient-centric Activities Within Clinical Research
- 1 October 2014
- Published by Elsevier in Clinical Therapeutics
- Vol. 36 (10) , 1349-1355
Taking the Pulse of Strategic Outsourcing Relationships
- 1 October 2014
- Published by Elsevier in Clinical Therapeutics
- Vol. 36 (10) , 1349-1355
Taking the Pulse of Strategic Outsourcing Relationships
- 1 January 2013
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 47 (1) , 101-109
Benchmarking the Study Initiation Process
The study start-up phase of a trial is an area that pharmaceutical and biotechnology companies are focusing on in order to reduce delays and improve efficiency. To better understand and examine metrics within study start-up, the Tufts Center for the Study of Drug Development, in collaboration with 11 pharmaceutical and biotechnology companies, examined a comprehensive set of metrics and analyzed study data from 105 global clinical trials. The results indicate that the early stages of the site initiation process are areas that accounted for the majority of cycle time. An examination of cycle time to the first patient in by therapeutic area also reveals variation. Variations in cycle time to the first patient occur by site type as well as by region. Academic institutions and government-funded sites were longest to the first patient in, while physician practices were fastest.
- 1 January 2013
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 47 (1) , 101-109
Benchmarking the Study Initiation Process
The study start-up phase of a trial is an area that pharmaceutical and biotechnology companies are focusing on in order to reduce delays and improve efficiency. To better understand and examine metrics within study start-up, the Tufts Center for the Study of Drug Development, in collaboration with 11 pharmaceutical and biotechnology companies, examined a comprehensive set of metrics and analyzed study data from 105 global clinical trials. The results indicate that the early stages of the site initiation process are areas that accounted for the majority of cycle time. An examination of cycle time to the first patient in by therapeutic area also reveals variation. Variations in cycle time to the first patient occur by site type as well as by region. Academic institutions and government-funded sites were longest to the first patient in, while physician practices were fastest.
- 1 September 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (5) , 573-580
Evaluating the Impact of Patient Recruitment and Retention Practices
- 1 September 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (5) , 573-580
Evaluating the Impact of Patient Recruitment and Retention Practices